Gene editing may one day cure the oral herpes virus. Here's why that virus is tough to tackle and how to prevent and minimize ...

Massachusetts families are still struggling to find alternatives almost a year after GlaxoSmithKline canceled a widely ...

With an accuracy of 86%, the biomarker panel has the potential to be clinically useful in diagnosis, management, and ...

The arrest in the slaying of UnitedHealthcare CEO Brian Thompson was the first step to putting his alleged killer behind bars ...

Maud Gatewood (1934–2004) is an essential figure in mid- and late-20th century art in North Carolina, both as an esteemed ...

British drugmaker AstraZeneca has appointed a new China head, replacing a former executive who has been detained by ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.90.

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today. The company’s shares opened today at ...

Mepolizumab, a biologic approved for asthma, is not currently approved for COPD, but data from a 2017 study showed a trend ...

Phase 1/2 study initiated for ATX-559, a first-in-class inhibitor of DHX9, focused on patients with BRCA1/2-deficient breast cancer and MSI-H and/or dMMR solid tumors LEXINGTON, Mass., Dec.

Inequalities in childhood vaccination are widening in England, with uptake rates of five key vaccines consistently lower in young children living in areas of higher deprivation from 2019 to 2023, ...

Objective To quantify changes in inequalities in uptake of childhood vaccination during a period of steadily declining overall childhood vaccination rates in England. Design Longitudinal study.